PET imaging of glutamine metabolism in a clinical trial of metastatic colorectal cancer

Conclusions: We have identified two PET imaging biomarkers for detection of response in patients treated with combined EGFR/glutamine metabolism-targeting therapy. These biomarkers could serve as an innovative imaging approach to help guide precision medicine by matching patients with cancer to the ideal treatment. This study could lead to critical advances in the treatment of CRC, as well as for other cancer types, by elucidating the mechanism of action of therapies targeting glutaminolysis.

Source: Journal of Nuclear Medicine - May 14, 2020 Category: Nuclear Medicine Authors: Cohen, A., Payne, A., Smith, G., Whisenant, J., Peterson, T., Ciombor, K., Cardin, D., Eng, C., Goff, L., Das, S., Coffey, R., Berlin, J., Manning, H. C. Tags: New Radiopharmaceuticals Source Type: research